5 alfa-reductase inhibitors not significantly associated with prostate cancer mortality: JAMA

There was no statistically significant correlation between the use of 5 alfa-reductase inhibitor (5-ARI) and prostate cancer (PCa) mortality in a recent systematic review and meta-analysis by Michael Baboudjian and colleagues, which draws on more than 3 million patients and more than 20 years' worth of epidemiologic literature. Nevertheless, the study offers valuable information for guiding clinical care. The findings of this study were published in JAMA Oncology.

Recently, conflicting findings on the relationship between the usage of 5-reductase inhibitors (5-ARI) and prostate cancer mortality have been revealed in a number of large, high-quality research. In order to carefully assess the available data relating the usage of 5-ARI and PCa mortality, this study was undertaken.

Through August 2022, a literature search was carried out utilizing the Embase, PubMed/Medline, and Web of Science databases. Studies were considered admissible if they compared 5-ARI users and nonusers in randomized clinical trials and prospective or retrospective cohort studies that examined PCa mortality in male patients of any age who were 5-ARI users. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) reporting standard were followed while reporting this study. HRs with adjustments were taken from publications that had already been published.